BMP4-GPX4 Axis Reduces Ferroptosis and Enhances Retinal Ganglion Cell Survival in Glaucoma Models

Study Background and Research Question

Glaucoma, characterized by progressive retinal ganglion cell (RGC) degeneration and vision loss, remains a leading cause of irreversible blindness worldwide. Elevated intraocular pressure (IOP) is a primary risk factor, but the molecular mechanisms driving RGC death are complex and incompletely understood. Recent evidence has implicated ferroptosis—a regulated, iron-dependent mode of cell death driven by excessive reactive oxygen species (ROS) and lipid peroxidation—as a critical contributor to RGC loss in high IOP glaucoma (Fang et al., 2025).

Retinal stem cell (RSC) transplantation offers a regenerative strategy by replenishing lost RGCs. However, the hostile post-injury microenvironment, rich in ROS and iron, impairs both transplanted cell survival and their differentiation into functional RGCs. The research by Fang et al. addresses a pivotal question: can modulating the BMP4-GPX4 signaling axis reduce ferroptosis and improve RSC differentiation in glaucomatous retinas?

Key Innovation from the Reference Study

The central innovation of Fang et al.'s work is the identification and mechanistic validation of the BMP4-GPX4 axis as a dual-action pathway in glaucoma. Activation of bone morphogenetic protein 4 (BMP4) signaling not only upregulates glutathione peroxidase 4 (GPX4), a major ROS-scavenging enzyme, but also fosters an environment conducive to RSC differentiation into mature RGCs under high IOP conditions (Fang et al., 2025).

This dual effect—suppressing ferroptotic cell death and enhancing neuroregeneration—addresses two fundamental challenges in experimental glaucoma therapy. It positions the BMP4-GPX4 module as a promising therapeutic target for both neuroprotection and integration of transplanted stem cells.

Methods and Experimental Design Insights

To model glaucoma, the researchers employed NMDA (N-Methyl-D-aspartic acid) as an excitotoxin, inducing RGC injury and simulating the pathological features of high IOP glaucoma. NMDA, a selective NMDA receptor agonist, reliably triggers calcium influx, oxidative stress, and subsequent neuronal death—mirroring key aspects of excitotoxicity-driven neurodegeneration (Fang et al., 2025). The study's workflow aligns with established protocols for excitotoxicity research (related article).

Key methodological steps included:

• Model induction: Intraocular administration of NMDA to create acute RGC damage.
• Immunofluorescence and molecular assays: Quantification of RGC markers (Brn3a), BMP4, and downstream SMAD signaling via qPCR and Western blotting.
• Oxidative stress and ferroptosis assessment: Measurement of ROS (fluorescence microscopy), glutathione (GSH), malondialdehyde (MDA), and Fe²⁺ levels, as well as ferroptosis markers (ACSL4, GPX4, SLC7A11).
• Bioinformatics validation: KEGG pathway enrichment using GEO datasets to confirm upregulation of stem cell pluripotency and BMP4 signaling.
• Functional transplantation: RSCs transplanted into glaucomatous retinas to evaluate differentiation and survival in the context of BMP4-GPX4 modulation.

Protocol Parameters

• assay | NMDA-induced excitotoxicity | 10–100 μM (intraocular) | mouse RGC/retina model, acute injury | Reflects literature standards for selective NMDA receptor activation in excitotoxicity studies | paper
• assay | ROS detection (DCFH-DA fluorescence) | Relative fluorescence units | assessment of oxidative stress/ferroptosis | Captures degree of cellular oxidative stress post-NMDA exposure | paper
• assay | GSH/MDA/Fe²⁺ quantification | nmol/mg protein | evaluation of ferroptosis markers | Directly measures antioxidant capacity and lipid peroxidation | paper
• assay | BMP4/GPX4/SMAD1/3/5 expression (qPCR, WB) | fold-change vs. control | pathway activation quantification | Mechanistic correlation with ferroptosis and RSC differentiation | paper
• assay | RSC transplantation | ≥10⁴ cells/eye | in vivo differentiation/survival | Standard cell dose for murine retinal transplantation | workflow_recommendation

Core Findings and Why They Matter

Fang et al. present a comprehensive mechanistic and phenotypic analysis:

• NMDA successfully induces glaucoma-like RGC injury: Immunofluorescence for Brn3a confirms significant RGC loss and validates the model's fidelity (Fang et al., 2025).
• Ferroptosis is a major driver of RGC degeneration: Elevated ROS, depleted GSH, increased MDA, and iron accumulation indicate a robust ferroptotic phenotype.
• BMP4 expression and downstream SMAD signaling are upregulated in the glaucomatous retina: Both transcript and protein levels rise significantly, as confirmed by qPCR and Western blot.
• BMP4-GPX4 modulation reduces oxidative and ferroptotic stress: Intervention experiments show increased GPX4 expression, lower ROS, restored GSH, and reduced lipid peroxidation in RGCs.
• Enhanced RSC differentiation and survival: The microenvironment created by BMP4-GPX4 signaling supports more efficient RSC integration and differentiation into RGCs—an essential step for regenerative therapy efficacy.

These findings collectively support a model in which BMP4-GPX4 axis activation interrupts the ferroptosis cascade, preserves endogenous and transplanted RGCs, and creates a neuroprotective milieu, directly addressing the regenerative and neuroprotective challenges in glaucoma (Fang et al., 2025).

Comparison with Existing Internal Articles

Several internal resources contextualize and reinforce the methodological choices and translational impact of this study. For example, the article "NMDA (N-Methyl-D-aspartic acid): Mechanistic Insights and..." details the use of NMDA as a benchmark compound for modeling excitotoxicity and oxidative stress in neurodegeneration. Its focus on precise NMDA receptor agonism aligns with the reference study's use of NMDA to induce reproducible RGC injury.

Similarly, "BMP4-GPX4 Axis Mitigates Ferroptosis in Glaucoma RGC Models" provides additional mechanistic depth on how BMP4-driven GPX4 upregulation confers neuroprotection in the setting of oxidative injury, highlighting the translational relevance of the BMP4-GPX4 pathway for both basic and applied neuroscience.

These resources collectively validate the workflow—using NMDA-induced injury to model excitotoxicity and deploying BMP4-GPX4 modulation for neuroprotection—as a robust, reproducible platform for excitotoxicity research, oxidative stress assay, and neurodegenerative disease model development.

Limitations and Transferability

While the study robustly demonstrates BMP4-GPX4-mediated protection in a mouse model of acute glaucoma, several limitations warrant consideration:

• Species and model specificity: Findings in NMDA-induced murine models may not fully replicate the chronic, multifactorial pathology of human glaucoma.
• Acute vs. chronic injury: NMDA administration models rapid excitotoxicity rather than the slow progression typical of human disease (related article).
• Pathway complexity: While BMP4-GPX4 is pivotal, other regulatory axes likely contribute to RGC survival and stem cell integration.
• Translational hurdles: The efficacy and safety of BMP4-GPX4 pathway modulation in clinical contexts remain to be established.

Nevertheless, the protocol offers a well-controlled framework for studying excitotoxicity, ferroptosis, and neuroregeneration, with strong potential for adaptation to other oxidative stress and neurodegenerative disease models.

Research Support Resources

For researchers aiming to replicate or extend these workflows, NMDA (N-Methyl-D-aspartic acid) (SKU B1624, APExBIO) is widely used as a selective NMDA receptor agonist to induce excitotoxic injury, model calcium influx, and study oxidative stress in neuronal systems. Its high purity and well-characterized receptor specificity make it suitable for reproducible glaucoma and neurodegenerative disease modeling, including ferroptosis and calcium influx measurement (workflow_recommendation). Researchers should consult published protocols and product specifications for optimal dosing and storage to ensure assay integrity. This compound is intended for laboratory research use only.